Semaglutide vs Tirzepatide: Which Is Better?

For two years the honest answer to “which is better?” was “we can’t say for sure — there’s no direct comparison.” That changed. A head-to-head trial now exists, it was published in a top medical journal, and it gives a clear answer on the question most people are asking: which drug produces more weight loss. The short version is that tirzepatide does. But “more weight loss” and “better for you” are not the same question, so the rest of this page works through both.

The short answer

If your single goal is the largest average weight reduction, the evidence favors tirzepatide. In the only direct head-to-head trial, it outperformed semaglutide by a meaningful margin, and its own studies show higher peak weight loss.

If your situation is more complicated — you have established heart disease, a particular insurance plan, a history of not tolerating one of these well, or you simply can’t access one of them — then the “better” drug can flip. Semaglutide has a longer cardiovascular-outcomes track record and an FDA heart-risk indication that tirzepatide doesn’t yet have. Both are excellent medications by historical standards; this is a comparison between two strong options, not a good one and a bad one.

Same idea, two different molecules

Both drugs are weekly injections that mimic hormones your gut releases after eating — hormones that reduce appetite, slow stomach emptying, and quiet the “food noise” that drives overeating. The structural difference is simple and explains most of the results:

• Semaglutide activates a single receptor: GLP-1.
• Tirzepatide activates two receptors: GLP-1 and GIP. It’s the first FDA-approved “dual agonist” for weight management.

That second receptor (GIP) appears to add to the appetite and metabolic effect, which is the leading explanation for why tirzepatide tends to produce more weight loss.

The brand names cause endless confusion, so here’s the map:

One practical consequence: if you specifically want a pill, semaglutide is currently your only option between these two. Tirzepatide has no oral form.

What the head-to-head trial actually found

The trial is SURMOUNT-5, a randomized, open-label Phase 3b study of 751 adults with obesity (without type 2 diabetes), published in The New England Journal of Medicine in 2025. Participants took the maximum tolerated dose of either drug for 72 weeks.

The headline result: average weight loss of 20.2% with tirzepatide vs 13.7% with semaglutide — roughly 7.8 kg (about 17 lb) more on tirzepatide, or about a 47% greater relative reduction. Tirzepatide also won on every key secondary measure, including waist-circumference change and the share of people hitting 10%, 15%, 20%, and 25% weight-loss milestones.

Note: SURMOUNT-5 enrolled people without diabetes. Both drugs tend to produce somewhat less weight loss in people who also have type 2 diabetes, so these figures represent a roughly best-case, non-diabetic population.

This matters because before SURMOUNT-5, comparisons relied on lining up separate trials — useful, but never as reliable as randomizing the same population to both drugs. Now there’s a direct answer.

Putting the individual trial numbers in context

The head-to-head result lines up with each drug’s standalone studies:

• Semaglutide (STEP 1): about 14.9% average weight loss at 68 weeks.
• Tirzepatide (SURMOUNT-1): about 16.0%, 21.4%, and 22.5% at its three dose levels over 72 weeks — so up to roughly one-fifth to nearly one-quarter of body weight at the top dose.

A useful way to hold this in your head: semaglutide reliably delivers in the mid-teens percent range, while tirzepatide reaches the low-twenties. These are averages — real-world results vary widely, and plenty of people on semaglutide lose more than the tirzepatide average, while some on tirzepatide lose less. Adherence, the dose you can tolerate, diet, activity, sleep, and starting weight all move the number. Treat trial percentages as a guide to the typical gap between the drugs, not a promise of your personal result.

Side effects and tolerability

This is where the two are most alike. Both are dominated by gastrointestinal side effects — nausea, diarrhea, constipation, and vomiting — which are most common while the dose is being increased and tend to ease over time. In SURMOUNT-5, serious adverse events were uncommon and similar between groups (4.8% on tirzepatide, 3.5% on semaglutide), and an equal, small number of people in each group stopped because of side effects.

Both also carry the same major cautions:

• A boxed warning about thyroid C-cell tumors seen in rodents; both are contraindicated if you or your family have medullary thyroid carcinoma or MEN 2.
• Cautions around pancreatitis, gallbladder disease, severe kidney issues from dehydration, and pregnancy (not for use while pregnant or trying to conceive).

The honest takeaway on tolerability: there’s no reliable way to predict which drug you’ll tolerate better. Some people feel fine on one and miserable on the other for no obvious reason, which is one of the most common reasons people switch. This is a conversation for a prescriber who can monitor you — not something to self-manage.

Beyond weight loss: the other approved uses

“Which is better” changes if you have a second health goal, because the two drugs have earned different additional indications:

• Cardiovascular risk: Semaglutide (as Wegovy) is FDA-approved to reduce the risk of major cardiovascular events — heart attack, stroke, cardiovascular death — in adults with established heart disease plus obesity or overweight, based on the large SELECT trial. If you have known heart disease, that established outcomes evidence is a genuine point in semaglutide’s favor. Tirzepatide’s dedicated cardiovascular-outcomes trial is still ongoing as of 2026.
• Sleep apnea: Tirzepatide (as Zepbound) is approved for moderate-to-severe obstructive sleep apnea in adults with obesity — an indication semaglutide doesn’t hold. That can also be the difference in whether a plan covers it.
• Type 2 diabetes: Both are first-rate. Tirzepatide (Mounjaro) generally produces larger drops in blood sugar and weight; semaglutide (Ozempic) has the longer real-world and cardiovascular track record.

Note: Approvals and indications change. The points above are current as of this page’s last-updated date and should be confirmed against current FDA labeling before relying on them.

Cost and access in 2026

In 2026 the two are roughly comparable on price, and the old four-figure list prices are no longer the only option. Manufacturer self-pay programs put both within reach of cash-paying patients: Wegovy through NovoCare runs around the low-to-mid hundreds per month (with the new oral pill the cheapest branded entry), while Zepbound vials through LillyDirect sit in a similar band, with the highest doses costing a bit more and tied to prompt refills. With commercial insurance, what you actually pay comes down to your specific plan, your indication, and prior-authorization rules rather than the drug itself.

Two access realities are worth flagging here, with the detail handed off to dedicated pages: broad compounded versions of both drugs largely ended in 2025 once the shortages resolved, so “cheap compounded semaglutide/tirzepatide” is no longer a routine legal route; and coverage, not sticker price, is usually the deciding factor for most insured patients. For the current numbers and the coverage mechanics, see the cost and insurance pages linked below.

So which should you choose?

There’s no universal winner, but the decision usually comes down to a few clear lines:

• Lean tirzepatide if your main goal is maximum weight loss, you’ve plateaued on semaglutide, or you also have obstructive sleep apnea.
• Lean semaglutide if you have established cardiovascular disease (its outcomes evidence is stronger), you want or need a pill option, or it’s simply the one your insurance covers and tirzepatide isn’t.
• It may not matter much if both are covered, you tolerate either, and you’d be happy with mid-teens weight loss — in which case start with whichever your prescriber and plan make easiest, and switch later if needed.

Whichever way the comparison points, the choice belongs in a clinical conversation. A prescriber can weigh your history, screen for the contraindications above, handle the dose increases safely, and switch you if the first option doesn’t fit. This page is here to help you walk into that conversation informed — not to replace it.